Open AccessHeparin-induced thrombocytopenia in COVID-19: A systematic review
Author(s) -
Sulakshana Sulakshana,
Sudhansu Sekhar Nayak,
Siva Perumal,
Badri Prasad Das
Publication year - 2021
Publication title -
al-banǧ. maqālāt wa abḥāṯ fī al-taẖdīr wa-al-in’āš
Language(s) - English
Resource type - Journals
ISSN - 0259-1162
DOI - 10.4103/aer.aer_151_21
Subject(s) - medicine , heparin induced thrombocytopenia , heparin , thrombosis , pneumonia , comorbidity , covid-19 , intervention (counseling) , intensive care medicine , low molecular weight heparin , disease , psychiatry , infectious disease (medical specialty)
It has been more than a year since the whole world is struggling with COVID-19 pandemic and may experience resurgences in the near future. Along with severe pneumonia, this disease is notorious for extensive thromboembolic manifestations. That is why experts advocated aggressive anticoagulation as a part of the therapy since the beginning. However, from May 2020 onwards, cases of heparin-induced thrombocytopenia (HIT) are being reported. HIT in itself is an autoimmune entity leading to life-threatening thrombosis in the setting of thrombocytopenia. Continuation of heparin can have disastrous consequences in case of unrecognized HIT. Hence, timely recognition of HIT is of utmost value to modify the anticoagulation strategy and salvaging lives. We performed a systemic review trying to find all reported cases of HIT in COVID-19.